# Triomics

> Triomics builds oncology-specific AI infrastructure that turns messy, unstructured cancer patient records into structured, cited, actionable data. Its OncoLLM engine and workflow agents automate clinical trial matching, visit preparation, and cancer registry reporting for leading cancer centers, cutting manual chart review time while increasing trial enrollment. Founded in 2021 and headquartered in New York, the company is used by 4 of the top 10 U.S. cancer hospitals and raised a $22M Series B led by Battery Ventures in May 2026.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Sarim Khan (Co-Founder & CEO), Hrituraj Singh (Co-Founder & CTO)
- **Team size:** ~72 employees
- **Products:** OncoLLM, PRISM (Patient Records Interpretation for Semantic clinical trial Matching), Visit Preparation & Pre-Charting, Cancer Registry Curation
- **Notable:** Used by 4 of the top 10 U.S. News Best Hospitals for Cancer, Raised $22M Series B led by Battery Ventures (May 2026), passing $36M+ total funding, Peer-reviewed validation in Nature Digital Medicine and presentation at ASCO

## Products & services

- **OncoLLM** — The core large language model built specifically for oncology. It reasons across an entire patient chart - clinical notes, pathology, imaging, molecular data and scanned documents - and returns auditable, cited answers with source attribution.
- **PRISM (Patient Records Interpretation for Semantic clinical trial Matching)** — AI-powered clinical trial matching that screens patients against active trials and delivers cited evidence linked to pathology, molecular data and clinical notes. Reported 95% accuracy and a 40% increase in trial matches.
- **Visit Preparation & Pre-Charting** — Auto-generates pre-charting notes in physician-preferred formats, assembling current disease status, treatment timeline and biomarkers. Reported an 80% reduction in pre-charting time for new patient visits.
- **Cancer Registry Curation** — Produces structured abstractions for NAACCR, SEER, COC and QOPI measures, linking each field to source documentation with 96% accuracy so centers meet federal reporting deadlines.

## Achievements

- Used by 4 of the top 10 U.S. News Best Hospitals for Cancer
- Raised $22M Series B led by Battery Ventures (May 2026), passing $36M+ total funding
- Peer-reviewed validation in Nature Digital Medicine and presentation at ASCO
- 67% reduction in manual chart review time; 40% increase in trial matches; 30%+ increase in enrollment
- PRISM trial-matching reported at 95% accuracy; registry abstraction at 96% accuracy
- Y Combinator-backed; ~4x enterprise customer growth and ~10x recurring revenue growth in a year

## Latest updates

- **2026-05** — Raised $22M Series B led by Battery Ventures to scale oncology AI chart abstraction and expand adoption across cancer centers.
- **2026-06** — Featured in Forbes for using AI to help doctors treat cancer more quickly.
- **2026-05** — Announced peer-reviewed validation in Nature Digital Medicine documenting chart-review time and trial-enrollment gains.

## Links

- Website: https://triomics.com
- LinkedIn: http://www.linkedin.com/company/triomics
- Twitter/X: https://twitter.com/Triomicsinc

---

Profile page: https://yespress.io/triomics
Published by YesPress — https://yespress.io
Last updated: 2026-07-17